Andrea S. James - 20 Jun 2024 Form 4 Insider Report for Oncocyte Corp (OCX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCX	Option to Purchase Common Stock	Award	$0	+200,000		$0.000000	200,000	20 Jun 2024	Common Stock	200,000	$2.87	Direct	F1, F2
transaction	OCX	Restricted Stock Units	Award	$0	+100,000	+50%	$0.000000	300,000	20 Jun 2024	Common Stock	100,000		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Granted on June 20, 2024 (the "Grant Date"), but such award is subject to shareholder approval of an increase in the number of shares available for issuance under the Oncocyte 2018 Equity Incentive Plan. Following such shareholder approval, an additional Form 4 will be filed with respect to the grant in accordance with pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended.
F2	The Option shall vest as follows, subject to the Reporting Person's continued compliance with any restrictive covenants by which the Reporting Person may be bound and continuous service as an employee of the Issuer or a Subsidiary from June 17, 2024, through the applicable vesting date: (A) twenty-five percent (25%) of the shares subject to the Option will vest and thereby become exercisable upon the one-year anniversary of the Grant Date, and (B) 75% of the shares subject to the Option will vest in thirty-six (36) substantially equal monthly installments thereafter.
F3	See Exhibit 99 attached hereto.